Skip to main content
Fig. 2 | Malaria Journal

Fig. 2

From: From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

Fig. 2

Survival, parasitaemia, and motor score of mice infected with Plasmodium berghei ANKA. Mice were either left untreated (n = 7; white quare) or were treated with RRx-001 (IV at 10 mg/kg; n = 7 mice; red circle) or artemether (IP at 50 mg/kg; n = 7, blue diamond), or 10 mg/kg IV of RRx-001 plus 50 mg/kg IP of artemether (n = 7, red circle with blue border). All parameters were measured at the same time points for all groups. The points were artificially displaced horizontally for clarity. a. Mice survival after infection. These data represent the trajectory of disease. At day 7 post infection, Kaplan-Meier survival curves were plotted and by day 12 differences in rates of survival in the various groups were observed: RRx-001 plus artemether 83 %, RRx-001 16.6 %, artemether 50 % and untreated 0 %. b. Mice parasitaemia after infection. Parasitaemia was monitored daily in surviving mice with Giemsa-stained thin blood smears from day 1 to day 12 post infection, and the mean ± SD for each group is shown. The parasitaemia peaks for all groups occurred between days 7–9. The parasitaemia in the untreated group increased progressively from the peak, while RRx-001, artemether decreased to almost zero levels and RRx-001 + artemether reached zero by Day 11. The percent change in parasitaemia after initiation of treatment with the combination of artemether-RRx-001 reaches 100 %; while artemether alone and RRx-001 approaches did not reach 100 %. c. Neurological motor scores after infection. Motor performance (modified SHIRPA test) for all groups was analysed. Motor behaviour drastically deteriorated in the untreated group while it rebounded in the treated groups, only returning to baseline i.e. to the level of uninfected groups in the RRx-001 + artemether cohort

Back to article page